Introduction
At present, the standard treatment for patients with metastatic prostate cancer is continuous hormonal therapy. The results of published studies involving medical or surgical castration, with or without antiandrogens, are all in general agreement, with a median progression-free survival of about 18 months and a median overall survival of only 30 months. 1 ± 4 This period is not very long and therefore, anything which could improve the survival would be welcome. The quality of life of patients with metastatic prostate cancer is not that good during treatment, and clinicians are seeking ways to maintain the ef®cacy of treatment while, at the same time, making it more easily tolerated. There are a number of possible ways to achieve these goals (Table 1) . Focusing on hormonal treatment, very precocious hormonal deprivation is one option, but the present paper will only examine intermittent hormonal therapy as a means of maintaining ef®cacy and improving tolerance.
Rationale for intermittent treatment schedules
There is a clear rationale for using intermittent androgen deprivation. For example, it is well known that when hormonal treatment is given to metastatic patients, they ultimately reach a hormone-refractory state due to the fact that apoptosis induced by androgen ablation is not able to eradicate all malignant cells, the remaining cells losing their apoptotic potential. 5, 6 However, three important points must be kept in mind: 7 prostatic cells need androgens in order to be able to differentiate, only differentiated cells are able to undergo apoptosis, and ®nally tumour cells surviving androgen ablation are forced into a normal pathway of differentiation with androgen replacement. 8 These three factors could be responsible for a delay in the onset of androgen refractory status. This has been clearly con®rmed by in vitro studies using two different cell-lines, the Shionogi 8, 9 and LNCaP models, 10,11 both of which produced similar results with a three-fold increase in the hormonosensitive period.
Thus, in men suffering from prostatic carcinoma there are a number of reasons for using intermittent androgen deprivation. It can help delay the onset of hormoneresistance, and may also be able to increase the overall survival and improve the quality of life. This last factor is very important since, in general, patients with metastatic prostate cancer have a poor quality of life. A reduction in overall health costs has also been seen as being possible, but no detailed pharmaco-economic analysis has yet been produced to substantiate this claim.
In light of currently available information on intermittent androgen blockade, it is known to be safe, and all published studies have shown that there is no hormone resistance after the ®rst cycle of intermittent castration. In addition, it has been con®rmed in several studies that the quality of life improves during`off-treatment' periods. 12, 13 
Intermittent maximal androgen blockade
The key question, however, is whether intermittent maximal androgen blocakde (IMAB) is better, equivalent to or worse than continuous maximal androgen blockade (CMBAB) in M1b patients in terms of survival. This has 14 ± 19 few have focused on the metastatic patients only, and none were randomized into continuous or intermittent hormonal suppression. The largest study so far carried out on M1b patients involved 43 men with a mean survival of 37 months. 20 More information on treatment ef®cacy is clearly required.
The European Takeda-sponsored EC 210 trial Currently, only two randomized studies devoted to the M1b patients are ongoing: SWOG 9346 and the European Takeda-sponsored trial EC 210. The EORTC conducted a phase II trial which is now closed and a phase III trial should be started shortly. We present the Takeda EC 210 trial, which is being carried out in patients with Tx, Nx Mlb/c prostate cancer in accordance with the methodology summarized in Table 2 .
To assist with standardization, one center in each country is charged with carrying out all measurements of PSA for that country, and the MAB regimen is used in both groups, with the only difference being that in one group it is`continuous' and in the other group it is intermittent'.
Several different quality-of-life (QoL) instruments are being used: QLQ C30 to monitor the general QoL, Lukacs questionnaires 21 for sexuality (which has been validated in the German and Italian languages and is currently evaluated in cancer patients) and the Madsen score for the voiding status.
Study design
The key details of the design of the trial are as follows ( Figure 1 ): patients with a PSA 20 ng/ml were given CMAB treatment for 6 months. Then if there was no clinical progression and if the PSA was below 4 ng/ml, they were centrally randomized to either CMAB or IMAB. Patients were then followed clinically with examinations every 3 months and a blood sample was taken every month to monitor the PSA level.
Follow-up
In the CMAB group, patients were followed until they exhibited hormone-independent progression. In the IMAB group, the treatment was stopped after randomization and was reintroduced when there was evidence of clinical progression or when the PSA rose above 10 ng/ ml. As soon as this occurred, the treatment was reintroduced for at least 3 months. The patient remained on treatment until the disappearance of any sign of clinical progression and the PSA level had fallen below 4 ng/ml. At that time the treatment was stopped again. This represents a complete treatment cycle. This pattern was repeated until the patient was progressive while on hormonal treatment. This hormone-independent progression was de®ned as three consecutive measurements of PSA 4 ng/ml or PSA greater than the nadir of the ongoing treatment cycle.
Study endpoint
The de®nition of progression involves either clinical (NPCP) or biological criteria: presence of a PSA above 4 ng/ml and increasing, or a PSA remaining stable but above 4 ng/ml, for at least two consecutive measurements 1 month apart. The primary endpoint of the study is overall survival.
Preliminary issues
Some preliminary questions had to be answered before the study got under way. The ®rst one was the con®rma-tion of the maintenance of hormonal sensitivity after the ®rst treatment reintroduction in the IMAB group. Also, as this was always observed from previous studies, it had to be tested again. Secondly the feasibility of the study was questionable concerning the number of patients required. We based our hypothesis on no more than 40% noneligible patients after the 6-month induction period. However, the most important question before starting the trial was acceptability of intermittent therapy by the patient. In France it is very unusual for a patient receiving a biologically effective treatment to have it interrupted, and to wait until a certain level of biological progression before restarting it. Therefore we wondered if patients would be willing to wait until their PSA rose to above 10 ng/ml. This was a key issue and the answers could be different in the three countries involved.
Current status
At the end of December 1998, a total of 128 patients had undergone the pre-selection procedure. Of these, 32 were still in the on-going induction period, while 15 patients had to be withdrawn. A further 33 patients were judged non-eligible after 6 months with CMAB, mainly because they had PSA levels b 4 ng/ml. Thus, the hypothetical ®gure of 40% for non-eligible patients was met, and the study was allowed to proceed. Most of the 15 withdrawals before randomization were due to the adverse effects of¯utamide. The others were due to very early progressive disease under CMAB.
Turning to the question of patient acceptability, so far no patient refused the allocated treatment, but during thè off' period, one patient randomized to IMAB with a rising PSA still below 10 ng/ml had to be convinced that there was no need for an early treatment reintroduction. So intermittent treatment appears to be acceptable to the majority of patients.
Finally, the treatment has been found to be safe and there was no hormonal resistance observed in the IMAB group after the ®rst treatment reintroduction. In regard to the drop-out rate due to progression, there was no difference between the IMAB and the CMAB groups as assessed by interim safety analyses planned and performed every 3 months.
Conclusion
The conclusion that can be drawn so far is that intermittent androgen suppression may be both safe and feasible. However, it should still be seen as experimental, with its impacts on survival and QoL remaining unknown until at least 300 patients have been recruited. It is expected that the ®rst clinical results will be available at the end of 2000. Meanwhile the study must go on.
